- Home
- NQP vs SIGA Comparison
NQP vs SIGA Comparison
Compare NQP & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NQP
- SIGA
- Stock Information
- Founded
- NQP 1990
- SIGA 1995
- Country
- NQP United States
- SIGA United States
- Employees
- NQP N/A
- SIGA N/A
- Industry
- NQP Trusts Except Educational Religious and Charitable
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- NQP Finance
- SIGA Health Care
- Exchange
- NQP Nasdaq
- SIGA Nasdaq
- Market Cap
- NQP 421.7M
- SIGA 443.4M
- IPO Year
- NQP N/A
- SIGA 1997
- Fundamental
- Price
- NQP $11.65
- SIGA $5.91
- Analyst Decision
- NQP
- SIGA
- Analyst Count
- NQP 0
- SIGA 0
- Target Price
- NQP N/A
- SIGA N/A
- AVG Volume (30 Days)
- NQP 58.4K
- SIGA 401.8K
- Earning Date
- NQP 01-01-0001
- SIGA 03-11-2025
- Dividend Yield
- NQP 3.21%
- SIGA 10.16%
- EPS Growth
- NQP N/A
- SIGA N/A
- EPS
- NQP N/A
- SIGA 1.20
- Revenue
- NQP N/A
- SIGA $173,731,386.00
- Revenue This Year
- NQP N/A
- SIGA $16.79
- Revenue Next Year
- NQP N/A
- SIGA $15.08
- P/E Ratio
- NQP N/A
- SIGA $4.94
- Revenue Growth
- NQP N/A
- SIGA 399.31
- 52 Week Low
- NQP $9.65
- SIGA $4.75
- 52 Week High
- NQP $11.89
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- NQP 58.25
- SIGA 43.23
- Support Level
- NQP $11.54
- SIGA $5.80
- Resistance Level
- NQP $11.67
- SIGA $6.25
- Average True Range (ATR)
- NQP 0.06
- SIGA 0.23
- MACD
- NQP 0.00
- SIGA 0.01
- Stochastic Oscillator
- NQP 56.52
- SIGA 43.44
About NQP Nuveen Pennsylvania Quality Municipal Income Fund
Nuveen Pennsylvania Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal and Pennsylvania income taxes and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal, Pennsylvania state and local income taxes. It invests a majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.